Skip to search formSkip to main contentSkip to account menu

A 86929

Known as: A-86929 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

PyridinesQuinolonesTetrahydronaphthalenesThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Catalytic enantioselective synthesis of A-86929, a dopamine D1 agonist.
A-86929, a dopamine D1 agonist was synthesized with 95% ee in five steps with overall yield of 56% via catalytic enantioselective… 
Review
2011
Review
2011
The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413
The novel selective D1 dopaminergic full agonists A-68930, A-77636 were discovered by the synthesis of molecules to probe the… 
Review
2006
Review
2006
Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data.
Adrogolide (ABT-431; DAS-431) is a chemically stable prodrug that is converted rapidly (<1 min) in plasma to A-86929, a full… 
2004
2004
Construction of arene-fused-piperidine motifs by asymmetric addition of 2-trityloxymethylaryllithiums to nitroalkenes: the asymmetric synthesis of a dopamine D1 full agonist, A-86929.
The straightforward methodology for the construction of chiral arene-fused-piperidine motifs using a highly enantioselective… 
1999
1999
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets
Abstract Common marmosets show parkinsonian motor deficits following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP… 
Highly Cited
1999
Highly Cited
1999
ABT‐431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease
Studies in animal models show a selective D1 receptor agonist with full functional efficacy compared with dopamine to have… 
1997
1997
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys
The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear. The… 
1997
1997
The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
The ability of the selective dopamine D1 receptor agonist (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-aza cyclopent-1… 
1997
1997
An Efficient Enantioselective Synthesis of the D1 Agonist (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia- 5-azacyclopenta[c]phenanthrene-9,10-diol (A-86929).
(5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia-5-azacyclopenta[c]phenanthrene-9,10-diol (A-86929, 1), a potent selective… 
Highly Cited
1996
Highly Cited
1996
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
(-)-Trans 9,10-hydroxy-2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5- azacyclopent-1-ena[c]phenanthrene hydrochloride (A-86929) is a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)